Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Feb;71(3):315-8.
doi: 10.1007/s11060-004-2028-0.

Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma

Ying-Wen Su  1 , Ming-Chih Chang, Ming-Fu Chiang, Ruey-Kuen Hsieh
Affiliations
Review

Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma

Ying-Wen Su et al. J Neurooncol. 2005 Feb.

Abstract

In patients with recurrent malignant glioma, treatment-related myelodysplastic syndrome (t-MDS) and acute leukemia are rare adverse effects because the median survival after relapse is limited. We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ). A cytogenetic study showed del (3)(q11.1). MDS was diagnosed 8.4 months after beginning TMZ. The disease rapidly evolved into acute leukemia within 1 month after the onset of MDS, and the patient died 1 month later during induction chemotherapy. The prognosis of t-MDS is generally poor. Considering the increasing use of TMZ, which is regarded as a drug with moderate toxicity, careful follow-up with routine blood testing is vital.

PubMed Disclaimer

References

    1. J Clin Oncol. 1998 Mar;16(3):1008-12 - PubMed
    1. Cancer Res. 1992 May 1;52(9):2419-23 - PubMed
    1. Cancer Res. 2001 Apr 15;61(8):3439-42 - PubMed
    1. Semin Oncol. 2001 Aug;28(4 Suppl 13):3-12 - PubMed
    1. Eur J Cancer. 1991;27(4):427-30 - PubMed

MeSH terms